COSTEM 2021 | The role of allo-HSCT in treating relapsed patients with multiple myeloma
Gösta Gahrton, MD, Karolinska University Hospital, Stockholm, Sweden, discusses the role of allogeneic hematopoietic stem cell transplantation (allo-HSCT) as salvage therapy in multiple myeloma. Some studies have shown that relapsed patients who undergo a combination of allo-HSCT and autologous hematopoietic stem cell transplantation (auto-HSCT) have a longer long-term overall survival (OS) than patients who only receive auto-HSCT. Other studies have reported high short-term OS in relapsed patients treated with novel conditioning and consolidation approaches, including bortezomib after auto-HSCT. Dr Gahrton argues that allo-HSCT might be beneficial for high-risk patients and patients who have relapsed after auto-HSCT. In addition, Dr Gahrton describes how autologous chimeric antigen receptor T-cell therapy (CAR-T) could be consolidated with allo-HSCT, with early data on allogeneic chimeric antigen receptor T-cell (CAR-T) therapies showing efficacy in the relapsed setting. This interview took place at the 6th Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM), which took place virtually.
Disclosures
Gösta Gahrton, MD, has acted as an advisor for Fujimoto Pharmaceutical corporation; has received honoraria from Bristol Myers Squibb; and is a shareholder of XNK Therapeutics and AstraZeneca.
